2025 Q4 -tulosraportti
8 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenBioPorto reported a revenue increase of 11% to 40.3 MDDK in 2025, with significant growth in NGAL sales in the USA and revenue from new distributors from ProNephro AKI. https://www.inderes.se/research/bioporto-investerings-case-genomfor-framatstrategin-med-ansokan-for-vuxna-inlamnad-under-q1-2026?utm_source=nordnet&utm_medium=integration
·2 päivää sittenChatGPT’s assessment of today's KDIGO announcement for BioPorto: Yes — it is clearly positive for BioPorto. Here is the short explanation – and then a more detailed assessment of why the KDIGO draft is a strong positive indicator for BioPorto (NGAL-tests), both commercially and regulatorily. ⸻ ✅ Short answer: The KDIGO 2026 draft's way of including biomarkers is a significantly positive development for BioPorto, because: 1. Biomarkers are now for the first time genuinely incorporated into KDIGO’s diagnostic framework. 2. NGAL is one of the most important and most validated early AKI injury markers. 3. When KDIGO shifts diagnostics from “only creatinine and urine output” → to “function + injury”, NGAL becomes necessary. 4. Hospitals follow KDIGO. When the guideline shifts, the market shifts. ⸻ Why it is positive for BioPorto – detailed 1️⃣ KDIGO now officially opens for biomarkers This has never happened before in the AKI guideline. When KDIGO: • writes an entire chapter on biomarkers • creates tables dedicated to “select kidney biomarkers” • includes NGAL in the biomarker list • mentions multimarker strategies … it means that biomarkers are normalized in clinical practice. For BioPorto, this means: ➡️ AKI-tests go from “nice-to-have” to guideline-supported diagnostics. ⸻ 2️⃣ NGAL is in the top 3 of the most studied AKI-biomarkers KDIGO will only include biomarkers in the tables if they are: • robust • validated • clinically applicable NGAL fulfills all three. TIMP-2·IGFBP7 and KIM-1 do too — but NGAL has more studies and a longer history. ➡️ If KDIGO mentions NGAL in the biomarker section, it indirectly becomes an endorsement. BioPorto is one of the few that has a regulatorily clear NGAL-test (cf. The NGAL Test™). ⸻ 3️⃣ KDIGO’s new approach → multimarker = greater clinical adoption The draft shows that KDIGO is moving towards: • injury + function • early warning + progression • risk stratification This is the setup for NGAL. BioPorto sells precisely the type of test that KDIGO now plans to highlight as a necessity. ⸻ 4️⃣ When KDIGO changes, strategic purchasers change This is essential: • Hospital systems • ICU protocols • Pediatric nephrology • Sepsis and surgical pathways All lean directly on KDIGO. This means: When the final guideline comes, the market for NGAL-tests will grow significantly. BioPorto stands well here, especially because: • There are few competing NGAL suppliers with CE-IVDR / FDA pathways. • BioPorto specializes in NGAL in precisely clinical scenarios such as children and critically ill patients. ⸻ 5️⃣ The KDIGO draft comes simultaneously with increased regulatory momentum In recent years, BioPorto has: • achieved pediatric positioning • secured partnership in the USA • reached relevant IVDR and FDA milestones • strengthened focus on ICU/ER And now comes the KDIGO draft, which potentially accelerates global adoption. ➡️ It hits at a perfect time for BioPorto, commercially and strategically. ⸻ Overall assessment: This is the strongest guideline-related “pre-signal” for NGAL ever. And therefore significantly positive for BioPorto. If biomarkers end up in the final guideline — even just as “can be used for X” — it is a game changer for the market. BioPorto is positioned to be a leading supplier of NGAL in precisely this clinical application. ⸻- ·2 päivää sittenBioPorto submits request for FDA pre‑submission for U.S. adult program for urine‑NGAL after positive EPACRA‑analysis of AKI‑cut‑off https://www.globenewswire.com/news-release/2026/03/31/3265802/0/en/BioPorto-Advances-U-S-Adult-Urine-NGAL-Program-with-FDA-Pre-Submission-Request-After-Positive-EPACRA-AKI-Cut-Off-Analysis.html·1 päivä sittenBioPorto (investment case): Implement future strategy with adult application submitted in Q1 2026 Close yesterday at 16:38 ∙ Inderes In connection with the publication of BioPorto's annual report for 2025 and the latest announcements, we have updated our investment case. 2025 was a year of strategic repositioning for BioPorto. Revenue increased by 11% to 40,3 MDKK, driven by a 25% growth in NGAL RUO sales in the USA to 18,4 MDKK and the first distributor revenue for ProNephro AKI of 4,3 MDKK via Roche. The gross margin improved to 75% from 68%, while the adjusted EBITDA loss increased to -76,5 MDKK (from -70,6 MDKK) as research and development costs rose to 50,5 MDKK, driven by the adult clinical trial. BioPorto ended 2025 with 44 active hospitals in the USA and 54,9 MDKK in cash after two private placements totaling approx. 77 MDKK.
- ·27.3.I can understand that there are several who are not aware of why the NGAL test for children has been approved before the NGAL test for adults. The short version is that the previous management tried to get a test approved that would apply to both children and adults. The FDA would not approve that, so therefore the condition for an approval was that the test should be divided into children and adults, as it is now. The FDA also demanded that it should be the children's test that should be approved first and then for adults. It is entirely up to the FDA how and in what way it should proceed, and it is also up to the FDA how long it takes. They have some objectives for deadlines; whether they meet them is up to the FDA.
27.3.27.3.Tämä julkaisu on poistettu.·27.3.Bagerbrød Thanks for an, as usual, interesting dialogue. If you don't want posts deleted, then the best recommendation is that you maintain an objective angle and don't spice it up with irrelevant angles, such as other debaters "painting a gloomy picture". Now 3D is on the scene with something similar, and wants to focus on the world being unfair and NN not supporting 3D's desired censorship. Can't you @Bager, suggest to 3D that he mans up and actively participates in the debate and accepts that questions are asked when participating in a discussion forum. With wishes for a good weekend from here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
8 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenBioPorto reported a revenue increase of 11% to 40.3 MDDK in 2025, with significant growth in NGAL sales in the USA and revenue from new distributors from ProNephro AKI. https://www.inderes.se/research/bioporto-investerings-case-genomfor-framatstrategin-med-ansokan-for-vuxna-inlamnad-under-q1-2026?utm_source=nordnet&utm_medium=integration
- ·2 päivää sittenChatGPT’s assessment of today's KDIGO announcement for BioPorto: Yes — it is clearly positive for BioPorto. Here is the short explanation – and then a more detailed assessment of why the KDIGO draft is a strong positive indicator for BioPorto (NGAL-tests), both commercially and regulatorily. ⸻ ✅ Short answer: The KDIGO 2026 draft's way of including biomarkers is a significantly positive development for BioPorto, because: 1. Biomarkers are now for the first time genuinely incorporated into KDIGO’s diagnostic framework. 2. NGAL is one of the most important and most validated early AKI injury markers. 3. When KDIGO shifts diagnostics from “only creatinine and urine output” → to “function + injury”, NGAL becomes necessary. 4. Hospitals follow KDIGO. When the guideline shifts, the market shifts. ⸻ Why it is positive for BioPorto – detailed 1️⃣ KDIGO now officially opens for biomarkers This has never happened before in the AKI guideline. When KDIGO: • writes an entire chapter on biomarkers • creates tables dedicated to “select kidney biomarkers” • includes NGAL in the biomarker list • mentions multimarker strategies … it means that biomarkers are normalized in clinical practice. For BioPorto, this means: ➡️ AKI-tests go from “nice-to-have” to guideline-supported diagnostics. ⸻ 2️⃣ NGAL is in the top 3 of the most studied AKI-biomarkers KDIGO will only include biomarkers in the tables if they are: • robust • validated • clinically applicable NGAL fulfills all three. TIMP-2·IGFBP7 and KIM-1 do too — but NGAL has more studies and a longer history. ➡️ If KDIGO mentions NGAL in the biomarker section, it indirectly becomes an endorsement. BioPorto is one of the few that has a regulatorily clear NGAL-test (cf. The NGAL Test™). ⸻ 3️⃣ KDIGO’s new approach → multimarker = greater clinical adoption The draft shows that KDIGO is moving towards: • injury + function • early warning + progression • risk stratification This is the setup for NGAL. BioPorto sells precisely the type of test that KDIGO now plans to highlight as a necessity. ⸻ 4️⃣ When KDIGO changes, strategic purchasers change This is essential: • Hospital systems • ICU protocols • Pediatric nephrology • Sepsis and surgical pathways All lean directly on KDIGO. This means: When the final guideline comes, the market for NGAL-tests will grow significantly. BioPorto stands well here, especially because: • There are few competing NGAL suppliers with CE-IVDR / FDA pathways. • BioPorto specializes in NGAL in precisely clinical scenarios such as children and critically ill patients. ⸻ 5️⃣ The KDIGO draft comes simultaneously with increased regulatory momentum In recent years, BioPorto has: • achieved pediatric positioning • secured partnership in the USA • reached relevant IVDR and FDA milestones • strengthened focus on ICU/ER And now comes the KDIGO draft, which potentially accelerates global adoption. ➡️ It hits at a perfect time for BioPorto, commercially and strategically. ⸻ Overall assessment: This is the strongest guideline-related “pre-signal” for NGAL ever. And therefore significantly positive for BioPorto. If biomarkers end up in the final guideline — even just as “can be used for X” — it is a game changer for the market. BioPorto is positioned to be a leading supplier of NGAL in precisely this clinical application. ⸻
- ·2 päivää sittenBioPorto submits request for FDA pre‑submission for U.S. adult program for urine‑NGAL after positive EPACRA‑analysis of AKI‑cut‑off https://www.globenewswire.com/news-release/2026/03/31/3265802/0/en/BioPorto-Advances-U-S-Adult-Urine-NGAL-Program-with-FDA-Pre-Submission-Request-After-Positive-EPACRA-AKI-Cut-Off-Analysis.html·1 päivä sittenBioPorto (investment case): Implement future strategy with adult application submitted in Q1 2026 Close yesterday at 16:38 ∙ Inderes In connection with the publication of BioPorto's annual report for 2025 and the latest announcements, we have updated our investment case. 2025 was a year of strategic repositioning for BioPorto. Revenue increased by 11% to 40,3 MDKK, driven by a 25% growth in NGAL RUO sales in the USA to 18,4 MDKK and the first distributor revenue for ProNephro AKI of 4,3 MDKK via Roche. The gross margin improved to 75% from 68%, while the adjusted EBITDA loss increased to -76,5 MDKK (from -70,6 MDKK) as research and development costs rose to 50,5 MDKK, driven by the adult clinical trial. BioPorto ended 2025 with 44 active hospitals in the USA and 54,9 MDKK in cash after two private placements totaling approx. 77 MDKK.
- ·27.3.I can understand that there are several who are not aware of why the NGAL test for children has been approved before the NGAL test for adults. The short version is that the previous management tried to get a test approved that would apply to both children and adults. The FDA would not approve that, so therefore the condition for an approval was that the test should be divided into children and adults, as it is now. The FDA also demanded that it should be the children's test that should be approved first and then for adults. It is entirely up to the FDA how and in what way it should proceed, and it is also up to the FDA how long it takes. They have some objectives for deadlines; whether they meet them is up to the FDA.
- 27.3.27.3.Tämä julkaisu on poistettu.·27.3.Bagerbrød Thanks for an, as usual, interesting dialogue. If you don't want posts deleted, then the best recommendation is that you maintain an objective angle and don't spice it up with irrelevant angles, such as other debaters "painting a gloomy picture". Now 3D is on the scene with something similar, and wants to focus on the world being unfair and NN not supporting 3D's desired censorship. Can't you @Bager, suggest to 3D that he mans up and actively participates in the debate and accepts that questions are asked when participating in a discussion forum. With wishes for a good weekend from here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
8 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenBioPorto reported a revenue increase of 11% to 40.3 MDDK in 2025, with significant growth in NGAL sales in the USA and revenue from new distributors from ProNephro AKI. https://www.inderes.se/research/bioporto-investerings-case-genomfor-framatstrategin-med-ansokan-for-vuxna-inlamnad-under-q1-2026?utm_source=nordnet&utm_medium=integration
- ·2 päivää sittenChatGPT’s assessment of today's KDIGO announcement for BioPorto: Yes — it is clearly positive for BioPorto. Here is the short explanation – and then a more detailed assessment of why the KDIGO draft is a strong positive indicator for BioPorto (NGAL-tests), both commercially and regulatorily. ⸻ ✅ Short answer: The KDIGO 2026 draft's way of including biomarkers is a significantly positive development for BioPorto, because: 1. Biomarkers are now for the first time genuinely incorporated into KDIGO’s diagnostic framework. 2. NGAL is one of the most important and most validated early AKI injury markers. 3. When KDIGO shifts diagnostics from “only creatinine and urine output” → to “function + injury”, NGAL becomes necessary. 4. Hospitals follow KDIGO. When the guideline shifts, the market shifts. ⸻ Why it is positive for BioPorto – detailed 1️⃣ KDIGO now officially opens for biomarkers This has never happened before in the AKI guideline. When KDIGO: • writes an entire chapter on biomarkers • creates tables dedicated to “select kidney biomarkers” • includes NGAL in the biomarker list • mentions multimarker strategies … it means that biomarkers are normalized in clinical practice. For BioPorto, this means: ➡️ AKI-tests go from “nice-to-have” to guideline-supported diagnostics. ⸻ 2️⃣ NGAL is in the top 3 of the most studied AKI-biomarkers KDIGO will only include biomarkers in the tables if they are: • robust • validated • clinically applicable NGAL fulfills all three. TIMP-2·IGFBP7 and KIM-1 do too — but NGAL has more studies and a longer history. ➡️ If KDIGO mentions NGAL in the biomarker section, it indirectly becomes an endorsement. BioPorto is one of the few that has a regulatorily clear NGAL-test (cf. The NGAL Test™). ⸻ 3️⃣ KDIGO’s new approach → multimarker = greater clinical adoption The draft shows that KDIGO is moving towards: • injury + function • early warning + progression • risk stratification This is the setup for NGAL. BioPorto sells precisely the type of test that KDIGO now plans to highlight as a necessity. ⸻ 4️⃣ When KDIGO changes, strategic purchasers change This is essential: • Hospital systems • ICU protocols • Pediatric nephrology • Sepsis and surgical pathways All lean directly on KDIGO. This means: When the final guideline comes, the market for NGAL-tests will grow significantly. BioPorto stands well here, especially because: • There are few competing NGAL suppliers with CE-IVDR / FDA pathways. • BioPorto specializes in NGAL in precisely clinical scenarios such as children and critically ill patients. ⸻ 5️⃣ The KDIGO draft comes simultaneously with increased regulatory momentum In recent years, BioPorto has: • achieved pediatric positioning • secured partnership in the USA • reached relevant IVDR and FDA milestones • strengthened focus on ICU/ER And now comes the KDIGO draft, which potentially accelerates global adoption. ➡️ It hits at a perfect time for BioPorto, commercially and strategically. ⸻ Overall assessment: This is the strongest guideline-related “pre-signal” for NGAL ever. And therefore significantly positive for BioPorto. If biomarkers end up in the final guideline — even just as “can be used for X” — it is a game changer for the market. BioPorto is positioned to be a leading supplier of NGAL in precisely this clinical application. ⸻
- ·2 päivää sittenBioPorto submits request for FDA pre‑submission for U.S. adult program for urine‑NGAL after positive EPACRA‑analysis of AKI‑cut‑off https://www.globenewswire.com/news-release/2026/03/31/3265802/0/en/BioPorto-Advances-U-S-Adult-Urine-NGAL-Program-with-FDA-Pre-Submission-Request-After-Positive-EPACRA-AKI-Cut-Off-Analysis.html·1 päivä sittenBioPorto (investment case): Implement future strategy with adult application submitted in Q1 2026 Close yesterday at 16:38 ∙ Inderes In connection with the publication of BioPorto's annual report for 2025 and the latest announcements, we have updated our investment case. 2025 was a year of strategic repositioning for BioPorto. Revenue increased by 11% to 40,3 MDKK, driven by a 25% growth in NGAL RUO sales in the USA to 18,4 MDKK and the first distributor revenue for ProNephro AKI of 4,3 MDKK via Roche. The gross margin improved to 75% from 68%, while the adjusted EBITDA loss increased to -76,5 MDKK (from -70,6 MDKK) as research and development costs rose to 50,5 MDKK, driven by the adult clinical trial. BioPorto ended 2025 with 44 active hospitals in the USA and 54,9 MDKK in cash after two private placements totaling approx. 77 MDKK.
- ·27.3.I can understand that there are several who are not aware of why the NGAL test for children has been approved before the NGAL test for adults. The short version is that the previous management tried to get a test approved that would apply to both children and adults. The FDA would not approve that, so therefore the condition for an approval was that the test should be divided into children and adults, as it is now. The FDA also demanded that it should be the children's test that should be approved first and then for adults. It is entirely up to the FDA how and in what way it should proceed, and it is also up to the FDA how long it takes. They have some objectives for deadlines; whether they meet them is up to the FDA.
- 27.3.27.3.Tämä julkaisu on poistettu.·27.3.Bagerbrød Thanks for an, as usual, interesting dialogue. If you don't want posts deleted, then the best recommendation is that you maintain an objective angle and don't spice it up with irrelevant angles, such as other debaters "painting a gloomy picture". Now 3D is on the scene with something similar, and wants to focus on the world being unfair and NN not supporting 3D's desired censorship. Can't you @Bager, suggest to 3D that he mans up and actively participates in the debate and accepts that questions are asked when participating in a discussion forum. With wishes for a good weekend from here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt